Challenges in multiple sclerosis; how to define occurence of progression |
| |
Authors: | V.V. Brinar B. Barun |
| |
Affiliation: | 1. Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital, Prague, Czech Republic;2. Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA;3. IRCCS “S.Maria Nascente”, Don Gnocchi Foundation, Milan, Italy;4. Department of Radiology Charles University in Prague, First Faculty of Medicine and General University Hospital, Prague, Czech Republic;5. MR Imaging Clinical Translational Research Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA;1. Laboratoire Interdisciplinaire Carnot de Bourgogne, UMR 6303 CNRS-Université de Bourgogne, 9 Avenue Alain Savary, BP47870, F-21078 DIJON Cedex, France;2. Institut FEMTO-ST, UMR 6174 CNRS, Université de Franche-Comté, ENSMM, UTBM, 32 Avenue de l''observatoire, F-25044, BESANCON Cedex, France;1. Department of Neurology, State University of New York, Buffalo, NY, USA;2. Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic;3. Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, NY, USA;4. Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, USA;5. Department of Radiology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic |
| |
Abstract: | The challenges in MS are related to number of controversies in various aspects of disease but the relationship between relapses and disability progression, or aspects of MS as an inflammatory and/or neurodegenerative disease are extremely important because of its implications on prognosis and therapy of MS. MS was classically regarded as white matter inflammatory disease, while disability progression, brain and spinal cord atrophy were regarded as a consequence of global inflammation of NAWM and secondary involvement of grey matter. More recent histopathology studies, but also new, modern MRI techniques changed this view in MS as a prominent grey and white matter disease. Inflammatory demyelination of grey matter occurs early in MS sometimes even before occurrence of white matter lesions. Inspite of early therapy of MS with immunomodulatory drugs disability progression and neurodegeneration are still important and common part of MS pathogenesis. This indicate that treatment is not adequate to the predicted severity of MS, or perhaps to the basic pathogenetic mechanisms in MS. Beside acute clinical symptoms, conclusions about the severity of the disease are reflection of MRI sensitivity to detect focal WM lesions and insensitivity to detect grey matter lesions which correlate better with clinical symptoms. All presented studies and evaluations point to the necessity of changing the established diagnostic evaluation and treatment in MS. At the earliest stage of MS as well as in follow up of disease it would be necessary to apply a new MRI techniques more available for clinical practice such as DIR brain MR imaging at 3 T because of their sensitivity to detect grey matter lesions. In patient with present cortical lesions even in earliest stages of MS depending on severity of grey matter involvement more efficacious therapy like second or even third line therapy should start. |
| |
Keywords: | Multiple sclerosis Pathology Natural history studies MRI in MS brain atrophy Therapy of MS |
本文献已被 ScienceDirect 等数据库收录! |
|